Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial
Circulation: Cardiovascular Quality and Outcomes · 2025
DOI: 10.1161/circoutcomes.124.010849 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Quality and Outcomes, 2025. Verfasst von James Slater und 10 weiteren Autor:innen. Beteiligte Einrichtung: NYU Grossman School of Medicine, New York, NY (J.S., S.B., H.R.R., J.S.H.). Hauptthemen laut MEDLINE: Coronary Artery Bypass, Coronary Artery Disease, Myocardial Ischemia, Patient Selection. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: The appropriate use criteria for revascularization of stable ischemic heart disease have not been evaluated using randomized data. Using data from the randomized ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches; July 2012 to January 2018, 37 countries), the health status benefits of an invasive strategy over a conservative one were examined within appropriate use criteria scenarios. METHODS: Among 1833 participants mapped to 36 appropriate use criteria scenarios, symptom status was assessed using the Seattle Angina Questionnaire-7 at 1 year for each scenario and for each of the 6 patient characteristics used to define the scenarios. Coronary anatomy and SYNTAX(Synergy between percutaneous coronary intervention with Taxus and cardiac surgery) scores were measured using coronary computed tomography angiography. Treatment effects are expressed as an odds ratio for a better health status outcome with an invasive versus conservative treatment strategy using Bayesian hierarchical proportional odds models. Differences in the primary clinical outcome were similarly examined. RESULTS: The mean age was 63 years, 81% were male, and 71% were White. Diabetes was present in 28% and multivessel disease in 51%. Most clinical scenarios favored invasive for better 1-year health status. The benefit of an invasive strategy on Seattle Angina Questionnaire angina frequency scores was reduced for asymptomatic patients (odds ratio [95% credible interval], 1.16 [0.66–1.71] versus 2.26 [1.75–2.80]), as well as for those on no antianginal medications. Diabetes, number of diseased vessels, proximal left anterior descending coronary artery location, and SYNTAX score did not effectively identify patients with better health status after invasive treatment, and minimal differences in clinical events were observed. CONCLUSIONS: Applying the randomization scheme from the ISCHEMIA trial to appropriate clinical scenarios revealed baseline symptoms and antianginal therapy to be the primary drivers of health status benefits from invasive management. Consideration should be given to reducing the patient characteristics collected to generate appropriateness ratings to improve the feasibility of future data collection. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01471522.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NYU Grossman School of Medicine, New York, NY (J.S., S.B., H.R.R., J.S.H.).
- Department of Medicine, Stanford University School of Medicine, CA (D.J.M.).
- University of Missouri - Kansas City (UMKC)'s Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute (P.G.J., J.A.S., Z.F.).
- Icahn School of Medicine at Mount Sinai, New York, NY (G.W.S.).
- National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD (R.K.).
ORCID-Profile: James Slater, David J Maron, Philip G Jones, Sripal Bangalore, Harmony R Reynolds, Zhuxuan Fu, Gregg W Stone, Ruth Kirby, Judith S Hochman, John A Spertus
Förderung
- NCATS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Slater, J., Maron, D. J., Jones, P. G., Bangalore, S., Reynolds, H. R., Fu, Z., Stone, G. W., Kirby, R., Hochman, J. S., Spertus, J. A., & ISCHEMIA Research Group (2025). Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial. Circulation: Cardiovascular Quality and Outcomes. https://doi.org/10.1161/circoutcomes.124.010849
Vancouver
Slater J, Maron DJ, Jones PG, Bangalore S, Reynolds HR, Fu Z, et al. Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial. Circulation: Cardiovascular Quality and Outcomes. 2025. doi:10.1161/circoutcomes.124.010849
BibTeX
@article{Slater2025,
author = {Slater, James and Maron, David J and Jones, Philip G and Bangalore, Sripal and Reynolds, Harmony R and Fu, Zhuxuan and Stone, Gregg W and Kirby, Ruth and Hochman, Judith S and Spertus, John A and ISCHEMIA Research Group, ISCHEMIA Research Group},
title = {Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial},
journal = {Circulation: Cardiovascular Quality and Outcomes},
year = {2025},
doi = {10.1161/circoutcomes.124.010849}
}
EUVIMED